Phase 1B Study of PD-0332991 in Combination With T-DM1 in the Treatment of Patients With Advanced HER2 (Human Epidermal Growth Factor Receptor 2)-Positive Breast Cancer
Latest Information Update: 09 Feb 2022
Price :
$35 *
At a glance
- Drugs Palbociclib (Primary) ; Trastuzumab emtansine
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions
- 24 Jan 2022 Status changed from active, no longer recruiting to completed.
- 08 Jan 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.
- 13 Mar 2020 Planned number of patients changed from 33 to 28.